drugset / Trial / NCT03950414
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
NaSingle-groupOpen-labelTreatment
Summary
This study measures the tolerability of viral-specific T cells against Cytomegalovirus (CMV) in adult solid organ transplant (SOT) recipients. Participants are expected to be on study for 52 +/- 3 weeks.
Timeline
- Start
- 2019-09-27
- Primary completion
- 2022-07-11
- Completion
- 2022-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMV-specific T-cells | Cell therapy | 5000 cells/kg | Intravenous |
| Subject | CMV-specific T-cells | Cell therapy | 12500 cells/kg | Intravenous |
| Subject | CMV-specific T-cells | Cell therapy | 25000 cells/kg | Intravenous |